trending Market Intelligence /marketintelligence/en/news-insights/trending/TfuSD8XJsP7LDvqvPWN4JQ2 content esgSubNav
In This List

Lexicon's oral diabetes drug meets primary endpoint in phase 3 study

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Lexicon's oral diabetes drug meets primary endpoint in phase 3 study

Lexicon Pharmaceuticals Inc.'s investigational, oral diabetes drug sotagliflozin met its primary endpoint in a phase 3 clinical trial.

The company was studying the treatment in type 1 diabetes patients who were on insulin therapy. The study met its primary endpoint after demonstrating superiority over placebo and a well-tolerated safety profile during a 24-week treatment period.

Results from the study will be submitted for publication in a peer-reviewed journal.

The drug is also being studied in adults with type 2 diabetes.